Shares of Endo International plc (ENDP) are down 42c to $85.18 after the company reported fourth-quarter non-GAAP earnings of $800 million, or $1.16 per share. Analysts had been modeling $776.54 million and $1.12 per share.
For the full-year 2014, the company reported a loss of $721.3 million, or $4.91 per share. Revenue was reported as $2.88 billion.
Endo said it expects FY 2015 adjusted EPS of $4.35 to $4.55, with revenue in the range of $2.9 billion – $3 billion. Separately, the company announced today an agreement with Boston Scientific (BSX) for the sale of American Medical Systems’ Men’s Health and Prostate Health businesses as part of plan to fully divest the AMS business.
On valuation measures, Endo International PLC shares, which currently have an average 3-month trading volume of 2.6 million shares, trade at a forward P/E of 17.54 and a P/E to growth ratio of 2.63. The median Wall Street price target on the name is $90.00 with a high target of $101.00. Currently ticker boasts 12 ‘Buy’ endorsements, compared to 10 ’Holds’ and no ‘Sell’.
Profitability-wise, ENDP has a t-12 profit and operating margin of (54.23%) and 20.06%, respectively. The $13.16 billion market cap company reported $713.86 million in cash vs. $4.37 billion in debt in its most recent quarter.
ENDP currently prints a one year return of about 5.04% and a year-to-date return of around 18.69%.
The chart below shows where the equity has traded over the last 52 weeks.
Endo International PLC is a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. The firm was founded in 1920 and is headquartered in Dublin, Ireland.